UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
stimated average burden					
ours per response	2 0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * Benaim Ely				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455			3. Date of Earliest Transaction (Month/Day/Year) 03/07/2018						X Officer (give title below) Other (specify below) Chief Medical Officer						
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
ROCKVILLE, MD 20850 (City) (State) (Zip)				Table I - Non-Derivative Securities Acon						ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if		d 3. Date, if C	3. Transactio Code (Instr. 8)		A. Securities Acc A) or Disposed Instr. 3, 4 and 5 (A) or (D)	quired 5 (5)	Amount of Securities Beneficially wined Following Reported ransaction(s) nstr. 3 and 4)		eneficially d	6. 7. Ownership of Form: B Direct (D) O	Nature Findirect eneficial wnership nstr. 4)		
Reminder:	Report on a	separate line for eac	h class of securities	beneficia	ally	owned dir	rectly	Persoi contai	ly. ns who respo ned in this fo lisplays a cur	rm are r	not required	to respon	d unless th		74 (9-02)
									osed of, or Ber onvertible secu		Owned				
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisab	Expiration le Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 1.78	03/07/2018		A		200,000)	<u>(1)</u>	03/07/2028	8 Comm Stoc	1200 000	\$ 0	200,000	D	
Repor	ting O	wners													
D	on outing Or	unar Nama / Addre				Relatio	nship	os							

Donordino Omero Norre / Address	Relationships							
Reporting Owner Name / Address		10% Owner	Officer	Other				
Benaim Ely C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850			Chief Medical Officer					

Signatures

/s/ Douglas J. Swirsky, as attorney-in-fact for Ely Benaim	03/09/2018	
Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One quarter of the option vests and becomes exercisable on March 7, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.